63E vs NAMS: Side-by-Side Comparison
Compare ONWARD MEDICAL BV EO -12 (63E) and NewAmsterdam Pharma Company NV (NAMS) side by side: market cap EUR 174.52M vs USD 4.07B. Financials, growth and model signals on Bullrun.
| Metric | 63E | NAMS |
|---|---|---|
| Company | ONWARD MEDICAL BV EO -12 | NewAmsterdam Pharma Company NV |
| Country / Exchange | Netherlands · F | Netherlands · NASDAQ |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Market cap | EUR 174.52M | USD 4.07B |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Valuation model | — | — |
| Revenue (FY2025) | EUR 3.78M | USD 22.50M |
| Revenue growth YoY | +1550.7% | -50.6% |
| Net income | EUR -41.79M | USD -203.00M |
| Gross margin | 72.5% | — |
| Diluted EPS | -0.90 | -1.72 |
Figures are in each company's reporting currency — compare growth rates and margins rather than raw amounts.